Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
6.38
-0.06 (-0.93%)
At close: Dec 5, 2025, 4:00 PM EST
6.44
+0.06 (0.94%)
After-hours: Dec 5, 2025, 7:53 PM EST
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Aquestive Therapeutics stock have an average target of 10, with a low estimate of 7.00 and a high estimate of 17. The average target predicts an increase of 56.74% from the current stock price of 6.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $5 → $8 | Buy | Maintains | $5 → $8 | +25.39% | Nov 7, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $9 → $12 | Buy | Maintains | $9 → $12 | +88.09% | Oct 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +25.39% | Sep 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +56.74% | Jun 17, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $15 → $7 | Buy | Initiates | $15 → $7 | +9.72% | Jun 2, 2025 |
Financial Forecast
Revenue This Year
45.77M
from 57.56M
Decreased by -20.49%
Revenue Next Year
69.88M
from 45.77M
Increased by 52.69%
EPS This Year
-0.66
from -0.51
EPS Next Year
-0.55
from -0.66
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 48.1M | 87.8M | ||||
| Avg | 45.8M | 69.9M | ||||
| Low | 42.1M | 51.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -16.5% | 91.9% | ||||
| Avg | -20.5% | 52.7% | ||||
| Low | -26.9% | 11.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.65 | -0.09 | |||
| Avg | -0.66 | -0.55 | |||
| Low | -0.66 | -0.84 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.